keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation

keyword
https://www.readbyqxmd.com/read/29774423/diagnosis-and-management-of-gynecomastia-for-urologists
#1
REVIEW
Lee Baumgarten, Ali A Dabaja
PURPOSE OF REVIEW: Our aim is to review the steps of diagnosis and management of gynecomastia with a special focus on treatment of gynecomastia associated with androgen deprivation therapy for prostate cancer. RECENT FINDINGS: Recent studies investigating tamoxifen and radiation therapy for both therapy and prophylaxis of bicalutamide-induced gynecomastia are reviewed. Gynecomastia is a common clinical problem, affecting between one and two thirds of middle-aged men...
May 17, 2018: Current Urology Reports
https://www.readbyqxmd.com/read/29772100/radical-prostatectomy-in-t4-prostate-cancer-after-inductive-androgen-deprivation-results-of-a-single-institution-series-with-long-term-follow-up
#2
Turkan Hajili, Carsten H Ohlmann, Johannes Linxweiler, Christina Niklas, Martin Janssen, Stefan Siemer, Michael Stoeckle, Matthias Saar
OBJECTIVES: To determine the outcomes of complete surgical resection of T4 prostate cancer (PCa) after inductive androgen deprivation treatment (ADT). An inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet. PATIENTS AND METHODS: A monocentric RP database was queried for patients initially diagnosed with T4 PCa, considered as primary inoperable because of a fixed mass defined by rectal examination in combination with high PSA and/or large foci of biopsy-proven undifferentiated PCa...
May 17, 2018: BJU International
https://www.readbyqxmd.com/read/29765147/systemic-treatments-for-high-risk-localized-prostate-cancer
#3
REVIEW
Géraldine Pignot, Denis Maillet, Emmanuel Gross, Philippe Barthelemy, Jean-Baptiste Beauval, Friederike Constans-Schlurmann, Yohann Loriot, Guillaume Ploussard, Paul Sargos, Marc-Olivier Timsit, Sébastien Vincendeau, Gilles Pasticier, Delphine Borchiellini
The majority of patients with prostate cancer who later develop lethal metastatic disease have high-risk localized disease at presentation, emphasizing the importance of effective treatment strategies at this stage. Multimodal treatment approaches that combine systemic and local therapies offer a promising strategy for improving the clinical outcomes of patients with high-risk localized prostate cancer. Combinations of neoadjuvant and adjuvant chemotherapy, hormonal therapy, or chemohormonal therapy are considered to be the standard of care in most solid tumours and should be investigated in the future for the treatment of prostate cancer to improve patient outcomes...
May 15, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29764892/intense-exercise-for-survival-among-men-with-metastatic-castrate-resistant-prostate-cancer-interval-gap4-a-multicentre-randomised-controlled-phase-iii-study-protocol
#4
Robert U Newton, Stacey A Kenfield, Nicolas H Hart, June M Chan, Kerry S Courneya, James Catto, Stephen P Finn, Rosemary Greenwood, Daniel C Hughes, Lorelei Mucci, Stephen R Plymate, Stephan F E Praet, Emer M Guinan, Erin L Van Blarigan, Orla Casey, Mark Buzza, Sam Gledhill, Li Zhang, Daniel A Galvão, Charles J Ryan, Fred Saad
INTRODUCTION: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS AND ANALYSIS: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC)...
May 14, 2018: BMJ Open
https://www.readbyqxmd.com/read/29764692/combined-high-dose-rate-brachytherapy-and-external-beam-radiotherapy-for-clinically-localised-prostate-cancer
#5
Iosif Strouthos, Georgios Chatzikonstantinou, Nikolaos Zamboglou, Natasa Milickovic, Sokratis Papaioannou, Dimitra Bon, Constantinos Zamboglou, Claus Rödel, Dimos Baltas, Nikolaos Tselis
PURPOSE: To report the clinical outcomes and treatment-related toxicities after combined high-dose-rate (HDR) brachytherapy (BRT) with external beam radiotherapy (EBRT) for patients with clinically localised high-risk prostate cancer. MATERIAL AND METHODS: Between 2008 and 2012, three hundred and three consecutive patients with organ-confined high-risk prostate cancer were treated with definitive radiotherapy consisting of HDR-BRT followed by supplemental EBRT. The transrectal 3D-ultrasound-based HDR-BRT boost consisted of two single-fraction implants of 10...
May 12, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29764515/long-term-outcome-of-a-moderately-hypofractionated-intensity-modulated-radiotherapy-approach-using-an-endorectal-balloon-for-patients-with-localized-prostate-cancer
#6
Bin S Teh, Gary D Lewis, Weiyuan Mai, Ramiro Pino, Hiromichi Ishiyama, Edward Brian Butler
BACKGROUND: Technical advances in radiotherapy delivery have simultaneously enabled dose escalation and enhanced bladder and rectal sparing. However, the optimal radiation fractionation regimen for localized prostate cancer is unclear. Laboratory and clinical evidence suggest that hypofractionation may improve the therapeutic ratio of radiotherapy. We report our institutional outcomes using moderately hypofractionated, intensity-modulated radiotherapy (IMRT), and an endorectal balloon, with emphasis on long-term biochemical control and treatment-related adverse events in patients with localized prostate cancer...
April 17, 2018: Cancer communications
https://www.readbyqxmd.com/read/29761176/androgen-deprivation-therapy-is-associated-with-prolongation-of-qtc-interval-in-men-with-prostate-cancer
#7
Thiago Gagliano-Jucá, Thomas G Travison, Philip W Kantoff, Paul L Nguyen, Mary-Ellen Taplin, Adam S Kibel, Grace Huang, Richelle Bearup, Haley Schram, Robert Manley, Yusnie M Beleva, Robert R Edwards, Shehzad Basaria
Context: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events occurring early after initiation of ADT. Testosterone levels are inversely associated with corrected QT (QTc) interval duration; therefore, prolongation of QTc duration could be responsible for some of these events during ADT. Objective: To evaluate changes in QTc duration during ADT. Design and Interventions: A 6-month prospective cohort study that enrolled men with PCa about to undergo ADT (ADT group) and a control group of men who previously underwent prostatectomy for PCa and never received ADT (non-ADT group)...
May 1, 2018: Journal of the Endocrine Society
https://www.readbyqxmd.com/read/29760221/development-and-validation-of-a-prostate-cancer-genomic-signature-that-predicts-early-adt-treatment-response-following-radical-prostatectomy
#8
Mohammed Alshalalfa, R Jeffrey Karnes, Vidit Sharma, Voleak Choeurng, Hussam Al-Deen Ashab, Nicholas Erho, Bruce J Trock, Ashley E Ross, Kasra Yousefi, Harrison K Tsai, Shuang G Zhao, Jeffrey J Tosoian, Zaid Haddad, Mandeep Takhar, S Laura Chang, Daniel E Spratt, Firas Abdollah, Robert B Jenkins, Eric A Klein, Paul L Nguyen, Adam P Dicker, Robert B Den, Elai Davicioni, Felix Y Feng, Tamara L Lotan, Edward M Schaeffer
PURPOSE: Currently no genomic signature exists to distinguish men most likely to progress on adjuvant androgen deprivation therapy (ADT) after radical prostatectomy (RP) for high risk prostate cancer. Here we develop and validate a gene expression signature to predict response to postoperative ADT. EXPERIMENTAL DESIGN: A training set consisting of 284 RP patients was established after 1:1 propensity score matching metastasis between adjuvant-ADT(a-ADT) treated and no-ADT treated groups...
May 14, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29757697/molecular-drivers-of-metastatic-castrate-resistant-prostate-cancer-new-roads-to-resistance
#9
Phoebe A Huang, Douglas K Price, William D Figg
Numerous growth-inducing signaling pathways have been implicated in the development of metastatic castrate-resistant prostate cancer, but their cross-talk with androgen receptor functions remains poorly understood. A recent study published in Science Signaling by Chen et al. 1 has identified a novel androgen-mediated signaling axis driven by loss of SPDEF and gain of TGFBI to facilitate metastasis, which may explain the acquisition of resistance to androgen deprivation therapy. These findings suggest that therapeutic inhibition of androgen signaling may inadvertently promote castrate resistance by inhibiting tumor suppressive functions of the androgen receptor...
May 14, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29757577/supposed-pituitary-production-of-human-chorionic-gonadotropin-induced-by-androgen-deprivation-therapy
#10
Koji Yoshimura, Yoshiharu Nakashima, Kyohei Sugiyama, Naoki Kohei, Akitoshi Takizawa
INTRODUCTION: The main cause of slightly elevated human chorionic gonadotropin (HCG) after successful treatment of male germ cell tumors is considered to be pituitary-derived HCG. It is well known that pituitary-derived HCG is frequently detected in postmenopausal women. We evaluated the status of serum HCG in men with elevated gonadotropins, which were induced by androgen deprivation therapy, using commercially available assays. MATERIALS AND METHODS: We enrolled 44 patients with prostate cancer, who underwent luteinizing-hormone releasing hormone agonist treatment...
April 30, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29757368/the-long-noncoding-rna-landscape-of-neuroendocrine-prostate-cancer-and-its-clinical-implications
#11
Varune Rohan Ramnarine, Mohammed Alshalalfa, Fan Mo, Noushin Nabavi, Nicholas Erho, Mandeep Takhar, Robert Shukin, Sonal Brahmbhatt, Alexander Gawronski, Maxim Kobelev, Mannan Nouri, Dong Lin, Harrison Tsai, Tamara L Lotan, R Jefferey Karnes, Mark A Rubin, Amina Zoubeidi, Martin E Gleave, Cenk Sahinalp, Alexander W Wyatt, Stanislav V Volik, Himisha Beltran, Elai Davicioni, Yuzhuo Wang, Colin C Collins
Background: Treatment induced neuroendocrine prostate cancer (tNEPC) is an aggressive variant of late-stage metastatic castrate resistant (mCRPC) prostate cancer that commonly arises through neuroendocrine transdifferentiation (NEtD). Treatment options are limited, ineffective, and for most patients, results in death in less than a year. We previously developed a first-in-field patient-derived xenograft (PDX) model of NEtD. Longitudinal deep transcriptome profiling of this model enabled monitoring of dynamic transcriptional changes during NEtD and in the context of androgen deprivation...
May 10, 2018: GigaScience
https://www.readbyqxmd.com/read/29755405/dual-paraneoplastic-endocrine-syndromes-heralding-onset-of-extrapulmonary-small-cell-carcinoma-a-case-report-and-narrative-review
#12
Jill B Feffer, Natalia M Branis, Jeanine B Albu
Objective: Extrapulmonary small cell carcinoma (EPSCC) is rare and frequent metastases at presentation can complicate efforts to identify a site of origin. In particular, SCC comprises <1% of prostate cancers and has been implicated in castration resistance. Methods: Clinical, laboratory, imaging, and pathology data are presented. Results: A 56-year-old man with locally advanced prostate adenocarcinoma on androgen deprivation therapy presented with a clogged nephrostomy tube...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29752513/oligorecurrent-prostate-cancer-limited-to-lymph-nodes-getting-our-ducks-in-a-row-nodal-oligorecurrent-prostate-cancer
#13
Andrei Fodor, Andrea Lancia, Francesco Ceci, Maria Picchio, Morten Hoyer, Barbara Alicja Jereczek-Fossa, Piet Ost, Paolo Castellucci, Elena Incerti, Nadia Di Muzio, Gianluca Ingrosso
PURPOSE: Oligorecurrent prostate cancer with exclusive nodal involvement represents a common state of disease, amenable to local therapy. New radio-labeled tracers have enriched the possibility of cancer detection and treatment. In this review, we aim to illustrate the main nuclear medicine diagnostic options and the role of radiotherapy in this setting of patients. METHODS: We performed a PubMed search referring to the PRISMA guidelines to analyze the performance of PSMA- and choline-PET in detecting oligorecurrence limited to lymph nodes, and to review the main studies supporting either ablative stereotactic body radiotherapy or regional lymph node irradiation in this clinical setting...
May 11, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29750418/yang-dd-krasnova-a-nead-kt-et-al-androgen-deprivation-therapy-and-risk-of-rheumatoid-arthritis-in-patients-with-localized-prostate-cancer
#14
Vincenza Conteduca, Ugo De Giorgi, Gianfranco Lauletta
No abstract text is available yet for this article.
May 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29750398/body-composition-fatigue-and-exercise-in-patients-with-prostate-cancer-undergoing-androgen-deprivation-therapy
#15
Robert U Newton, Emily Jeffery, Daniel A Galvão, Carolyn McIntyre, Nigel Spry, David Joseph, Jim Denham, Dennis R Taaffe
OBJECTIVES: To investigate the association between lean mass (LM) and fat mass (FM) with fatigue and vitality before and following exercise in patients with prostate cancer already undergoing androgen deprivation therapy (ADT). SUBJECTS AND METHODS: Cross-sectional associations between lean and fat mass with fatigue and/or vitality measures were examined in 229 patients (43-90 years). Prospective analysis was undertaken in 129 patients who underwent 3-6 months exercise (predominantly resistance + aerobic)...
May 11, 2018: BJU International
https://www.readbyqxmd.com/read/29748958/functional-roles-and-potential-clinical-application-of-mirna-345-5p-in-prostate-cancer
#16
Ilker Tinay, Mingyue Tan, Bin Gui, Lillian Werner, Adam S Kibel, Li Jia
BACKGROUND: MicroRNAs (miRNAs) are small non-coding RNAs, which negatively regulate gene expression and impact prostate cancer (PCa) growth and progression. Circulating miRNAs are stable and detectable in cell-free body fluids, such as serum. Investigation of circulating miRNAs presents great potential in uncovering new insights into the roles of miRNAs in PCa diagnosis and therapy. METHODS: Using TaqMan miRNA quantitative reverse transcription polymerase chain reaction (RT-qPCR), we compared the expression levels of five miRNAs (miR-193a-3p, miR-9-3p, miR-335-5p, miR-330-3p, and miR-345-5p) in serum samples from 20 normal individuals without cancer, 25 patients with localized disease, 25 patients with hormone-naïve or hormone sensitive metastatic disease, and 25 patients with metastatic castration-resistant prostate cancer (CRPC)...
May 10, 2018: Prostate
https://www.readbyqxmd.com/read/29748904/androgen-receptor-signaling-in-castration-resistant-prostate-cancer-alters-hyperpolarized-pyruvate-to-lactate-conversion-and-lactate-levels-in-vivo
#17
Niki Zacharias, Jaehyuk Lee, Sumankalai Ramachandran, Sriram Shanmugavelandy, James McHenry, Prasanta Dutta, Steven Millward, Seth Gammon, Eleni Efstathiou, Patricia Troncoso, Daniel E Frigo, David Piwnica-Worms, Christopher J Logothetis, Sankar N Maity, Mark A Titus, Pratip Bhattacharya
PURPOSE: Androgen receptor (AR) signaling affects prostate cancer (PCa) growth, metabolism, and progression. Often, PCa progresses from androgen-sensitive to castration-resistant prostate cancer (CRPC) following androgen-deprivation therapy. Clinicopathologic and genomic characterizations of CRPC tumors lead to subdividing CRPC into two subtypes: (1) AR-dependent CRPC containing dysregulation of AR signaling alterations in AR such as amplification, point mutations, and/or generation of splice variants in the AR gene; and (2) an aggressive variant PCa (AVPC) subtype that is phenotypically similar to small cell prostate cancer and is defined by chemotherapy sensitivity, gain of neuroendocrine or pro-neural marker expression, loss of AR expression, and combined alterations of PTEN, TP53, and RB1 tumor suppressors...
May 10, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29748830/-give-me-five-ultra-hypofractionated-radiotherapy-for-localized-prostate-cancer-non-invasive-ablative-approach
#18
Giulia Marvaso, Giulia Riva, Delia Ciardo, Sara Gandini, Cristiana Fodor, Dario Zerini, Sarah Pia Colangione, Giorgia Timon, Stefania Comi, Raffaella Cambria, Federica Cattani, Ottavio De Cobelli, Roberto Orecchia, Barbara A Jereczek-Fossa
Ultra-hypofractionated radiotherapy (RT) is given over a shorter time with larger doses with respect to conventional fractionation in patients with localized prostate cancer (PCa). The use of hypofractionation is supported both from the radiobiological point of view (the low α/β-ratio in PCa and dose escalation) and from the rising number of clinical evidences. The aim of this study is to review our data regarding oncological outcomes, namely biochemical progression-free survival (b-PFS) and clinical progression-free survival (c-PFS), acute and long-term toxicities in patients treated with a ultra-hypofractionated RT...
May 10, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29744295/anticancer-activity-of-the-protein-kinase-c-modulator-hmi-1a3-in-2d-and-3d-cell-culture-models-of-androgen-responsive-and-androgen-unresponsive-prostate-cancer
#19
Maria H Jäntti, Virpi Talman, Kati Räsänen, Ilari Tarvainen, Hannu Koistinen, Raimo K Tuominen
Prostate cancer is one of the most common cancers in men. Although it has a relatively high 5-year survival rate, development of resistance to standard androgen-deprivation therapy is a significant clinical problem. Therefore, novel therapeutic strategies are urgently needed. The protein kinase C (PKC) family is a putative prostate cancer drug target, but so far no PKC-targeting drugs are available for clinical use. By contrast to the standard approach of developing PKC inhibitors, we have developed isophthalate derivatives as PKC agonists...
May 2018: FEBS Open Bio
https://www.readbyqxmd.com/read/29743948/the-current-state-of-prostate-cancer-treatment-in-trinidad-and-tobago
#20
REVIEW
Satyendra Persaud, Maliza Persaud, Lester Goetz, Dylan Narinesingh
Prostate cancer mortality in the Caribbean region is among the highest in the world and prostate cancer is the most common cancer in Trinidad and Tobago. There is a two-tiered healthcare system in Trinidad and Tobago, and prostate cancer related issues account for a significant percentage of urologists' workload. Delivery of care is sometimes constrained by limited financial resources. Prostate-specific antigen testing is widely available but there is no national guideline. Treatment options available include active surveillance, radical prostatectomy, external beam radiotherapy and brachytherapy...
2018: Ecancermedicalscience
keyword
keyword
104014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"